Skip to Content
  • Revenues ($M)
    $10,764
  • Revenue Percent Change
    10.9%
  • Profits ($M)
    $3,547
  • Profits Percent Change
    20.9%
  • Assets ($M)
    $19,505
  • Employees
    7,350
  • Market Value — as of March 31, 2016 ($M)
    $56,925
  • Previous Rank
    298
  • Morning Consult Brand Index
    C-

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Company Info

CEO
Michel Vounatsos
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Cambridge, MA
Websitehttp://www.biogen.com
Years on Fortune 500 List7
Employees7,350

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$10,76410.9%
Profits ($M)$3,54720.9%
Assets ($M)$19,505-
Total Stockholder Equity ($M)$9,373-
Market Value — as of March 31, 2016 ($M)$56,925-

Profit Ratios

Profit as % of Revenues33%
Profits as % of Assets18.2%
Profits as % of Stockholder Equity37.8%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)15.34
EPS % Change (from 2014)24%
EPS % Change (5 year annual rate)31.2%
EPS % Change (10 year annual rate)41.7%

Total Return

Total Return to Investors (2015)-9.8%
Total Return to Investors (5 year, annualized)35.5%
Total Return to Investors (10 year, annualized)21.1%